Cargando…

Omalizumab Use in Chronic Spontaneous Urticaria during Pregnancy and a Four Years' Follow-Up: A Case Report

Chronic spontaneous urticaria (CSU) is a benign skin disorder usually responsive to treatment; however, at times it can be difficult to control and become very debilitating. We discuss the case of a woman with CSU that was unresponsive to H1-antihistamines who was treated with omalizumab and became...

Descripción completa

Detalles Bibliográficos
Autores principales:	Losappio, Laura Michelina, Mirone, Corrado, Schroeder, Jan Walter, Scibilia, Joseph, Balossi, Luca, Pastorello, Elide Anna
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	S. Karger AG 2020
Materias:	Single Case
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7588681/ https://www.ncbi.nlm.nih.gov/pubmed/33173477 http://dx.doi.org/10.1159/000509179

Ejemplares similares

Tolerated drugs in subjects with severe cutaneous adverse reactions (SCARs) induced by anticonvulsants and review of the literature
por: De Luca, Fabrizio, et al.
Publicado: (2017)

Levofloxacin induced Stevens-Johnson syndrome/ toxic epidermal necrolysis overlap syndrome: case reports
por: Aversano, Maria Gloria, et al.
Publicado: (2014)

Identification of risk factors of severe hypersensitivity reactions in general anaesthesia
por: Mirone, Corrado, et al.
Publicado: (2015)

Serum tryptase detected during acute coronary syndrome is significantly related to the development of major adverse cardiovascular events after 2 years
por: Pastorello, Elide Anna, et al.
Publicado: (2015)

Case Report: Omalizumab for Chronic Spontaneous Urticaria in Pregnancy
por: Liao, Shuang-Lu, et al.
Publicado: (2021)

A Case of α-Gal-Unrelated Red Meat-Induced Urticaria Treated by Omalizumab
por: Kondo, Makoto, et al.
Publicado: (2021)

Tryptase as a marker of severity of aortic valve stenosis
por: Losappio, Laura M., et al.
Publicado: (2018)

New insights in Stevens Johnson syndrome/ toxic epidermal necrolysis syndrome
por: Schroeder, Jan, et al.
Publicado: (2014)

OMALIZUMAB IN TREATMENT-RESISTANT CHRONIC SPONTANEOUS URTICARIA
por: Godse, Kiran V
Publicado: (2011)

Profile of omalizumab in the treatment of chronic spontaneous urticaria
por: Labrador-Horrillo, Moises, et al.
Publicado: (2015)

Omalizumab's efficacy and safety against chronic spontaneous urticaria
por: Özdemir, Öner
Publicado: (2023)

Treatment of Chronic Spontaneous Urticaria with a Single Dose of Omalizumab: A Study of Four Cases
por: Subramaniyan, Radhakrishnan, et al.
Publicado: (2016)

Omalizumab in chronic spontaneous urticaria (CSU): experience in three cases
por: Valle, Solange Oliveira Rodrigues, et al.
Publicado: (2015)

Omalizumab is effective in the treatment of difficult-to-treat chronic spontaneous urticaria
por: Forgie, Jennifer, et al.
Publicado: (2014)

Use of biologics in chronic spontaneous urticaria – beyond omalizumab therapy?
por: Metz, Martin, et al.
Publicado: (2021)

Sex differences in the efficacy of omalizumab in the treatment of chronic spontaneous urticaria
por: Sirufo, Maria Maddalena, et al.
Publicado: (2022)

Omalizumab treatment for chronic spontaneous urticaria: data from Turkey
por: Kara, Rabia Oztas, et al.
Publicado: (2022)

Cost‐effectiveness of personalized omalizumab dosing for chronic spontaneous urticaria
por: Denman, Sarah, et al.
Publicado: (2022)

A severe cutaneous reaction caused by acetaminophen in a pediatric patient
por: Schroeder, Jan, et al.
Publicado: (2014)

Omalizumab treatment and outcomes in Chinese patients with chronic spontaneous urticaria, chronic inducible urticaria, or both
por: Chen, Yudi, et al.
Publicado: (2021)

Improving of psychological status and inflammatory biomarkers during omalizumab for chronic spontaneous urticaria
por: Diluvio, Laura, et al.
Publicado: (2020)

Role of Multiple Comorbidities and Therapies in Conditioning the Clinical Severity of DRESS: A Mono-Center Retrospective Study of 25 Cases
por: Toniato, Andrea, et al.
Publicado: (2021)

Omalizumab Updosing in Chronic Spontaneous Urticaria: an Overview of Real-World Evidence
por: Metz, Martin, et al.
Publicado: (2020)

Successful and Safe Treatment of Chronic Spontaneous Urticaria with Omalizumab in a Woman during Two Consecutive Pregnancies
por: Ghazanfar, Misbah Nasheela, et al.
Publicado: (2015)

Severe allergic symptoms to peach are a risk factor for severe symptoms to other plant food allergens
por: Mascheri, Ambra, et al.
Publicado: (2011)

Wheat and maize allergy: which allergens are involved and relationship with symptoms severity
por: Pastorello, Elide Anna, et al.
Publicado: (2011)

Position statement for the use of omalizumab in the management of chronic spontaneous urticaria in Indian patients
por: Godse, Kiran, et al.
Publicado: (2016)

Refractory Chronic Spontaneous Urticaria Treated With Omalizumab in an Adolescent With Common Variable Immunodeficiency
por: Comberiati, Pasquale, et al.
Publicado: (2019)

Cost Utility of Omalizumab Compared with Standard of Care for the Treatment of Chronic Spontaneous Urticaria
por: Graham, Jonathan, et al.
Publicado: (2016)

Response of FcεRI‐bearing leucocytes to omalizumab in chronic spontaneous urticaria
por: Alizadeh Aghdam, Mehran, et al.
Publicado: (2020)

Exploring Machine Learning Techniques to Predict the Response to Omalizumab in Chronic Spontaneous Urticaria
por: Sardina, Davide Stefano, et al.
Publicado: (2021)

Omalizumab Reduces Unplanned Healthcare Interactions in Irish Patients With Chronic Spontaneous Urticaria
por: Ridge, Katie, et al.
Publicado: (2021)

The course of COVID-19 in patients with chronic spontaneous urticaria receiving omalizumab treatment
por: Atayik, E., et al.
Publicado: (2022)

Multicentric and Observational Study of Omalizumab for Chronic Spontaneous Urticaria in Real-Life in Colombia
por: García-Gómez, Elizabeth, et al.
Publicado: (2022)

Omalizumab for Patients with Chronic Spontaneous Urticaria: A Narrative Review of Current Status
por: Casale, Thomas B., et al.
Publicado: (2023)

Case report: Severe chronic spontaneous urticaria successfully treated with omalizumab and dupilumab
por: Puxkandl, Viktoria, et al.
Publicado: (2023)

Omalizumab for chronic urticaria in Latin America
por: Wilches, Paul, et al.
Publicado: (2016)

Urticaria and angioedema as possible reactions of omalizumab
por: Ozbagcivan, Ozlem, et al.
Publicado: (2018)

Omalizumab for chronic spontaneous urticaria in “complex” patients: data from real-life clinical practice
por: Vollono, Laura, et al.
Publicado: (2019)

Socio-economic burden and resource utilisation in Italian patients with chronic urticaria: 2-year data from the AWARE study
por: Rossi, Oliviero, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_0k3svcmlmv304872j6qajk4eaa